Jonathan C. Javitt - 09 Apr 2025 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Chairman and Chief Scientist, Director, 10%+ Owner
Signature
/s/ Jonathan Javitt
Issuer symbol
NRXP
Transactions as of
09 Apr 2025
Net transactions value
$0
Form type
4
Filing time
10 Sep 2025, 15:36:07 UTC
Previous filing
18 Dec 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Javitt Jonathan C Chairman and Chief Scientist, Director, 10%+ Owner C/O NRX PHARMACEUTICALS, INC., 1201 ORANGE STREET, SUITE 600, WILMINGTON /s/ Jonathan Javitt 10 Sep 2025 0001303782

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 09 Apr 2025 Common Stock 125,000 $1.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued